Peptide conjugated, inosine-substituted antisense oligomer compound and method -> Monitor Keywords

Site News |

Monitor Keywords |

Monitor Archive |

Organizer |

Account Info |

12/29/05 - USPTO Class 514 | 45 views | #20050288246 | Prev - Next | About this Page

Peptide conjugated, inosine-substituted antisense oligomer compound and method

Title: Peptide conjugated, inosine-substituted antisense oligomer compound and method

Related Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), O-glycoside, , Nitrogen Containing Hetero Ring, Polynucleotide (e.g., Rna, Dna, Etc.)

Brief Patent Description - Full Patent Description - Patent Claims

The Patent Description & Claims data below is from USPTO Patent Application 20050288246, Peptide conjugated, inosine-substituted antisense oligomer compound and method.

It is claimed:

1. In a method for enhancing the cellular uptake of a substantially uncharged oligonucleotide analog compound, by forming a conjugate of the compound and an arginine-rich peptide effective to enhance the uptake of the compound into target cells, and where the compound includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which the compound is intended to bind, an improvement comprising substituting an inosine base for at least one guanine base in said string of bases in said compound so as to limit the number of contiguous guanine bases in said string to three or fewer.

2. The improvement of claim 1, wherein the inosine substitution is effective to limit the number of contiguous guanine bases in said string to two or fewer.

3. The improvement of claim 1, wherein at least two inosine bases are substituted in said string of bases.

4. The improvement of claim 1, wherein said substituting is effective to enhance the water solubility of the conjugate during a purification step involving conjugate binding to and release from an cationic ion exchange resin, relative to the same conjugate in the absence of the inosine substitution.

5. The improvement of claim 1, wherein said target nucleic acid region includes the start codon in an mRNA, and said substituting is effective to enhance the ability of the conjugate to block translation of the protein encoded by the mRNA, relative to the same conjugate in the absence of the inosine substitution.

6. The improvement of claim 1, wherein said target nucleic acid region includes a donor or acceptor splice site in an preprocessed mRNA, and said substituting is effective to enhance the ability of the conjugate to mask mRNA splicing at said target region, relative to the same conjugate in the absence of the inosine substitution.

7. The improvement of claim 1, wherein said target nucleic acid region includes a virally-encoded cis-acting element involved in viral replication, and said substituting is effective to enhance the ability of the conjugate to block viral replication, relative to the same conjugate in the absence of the inosine substitution.

8. The improvement of claim 1, wherein said arginine-rich peptide comprises 8 to 16 subunits selected from X subunits, Y subunits, and optional Z subunits, including at least six X subunits, at least two Y subunits, and at most three Z subunits, where >50% of said subunits are X subunits, and where (a) each X subunit independently represents arginine or an arginine analog, said analog being a cationic .alpha.-amino acid comprising a side chain of the structure R.sup.1N.dbd.C(NH.sub.2)R.sup.2, where R.sup.1 is H or R; R.sup.2 is R, NH.sub.2, NHR, or NR.sub.2, where R is lower alkyl or lower alkenyl and may further include oxygen or nitrogen; R.sup.1 and R.sup.2 may together form a ring; and the side chain is linked to said amino acid via R.sup.1 or R.sup.2; (b) each Y subunit independently represents a neutral amino acid --C(O)--(CHR).sub.n--NH--, where (i) n is 2 to 7 and each R is independently H or methyl, or (ii) n is 1 and R is a neutral side chain selected from substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, and aralkyl, wherein said neutral side chain, when selected from substituted alkyl, alkenyl, and alkynyl, includes at most one heteroatom for every four carbon atoms; and (c) each Z subunit independently represents an amino acid selected from alanine, asparagine, cysteine, glutamine, glycine, histidine, lysine, methionine, serine, and threonine.

9. The improvement of claim 8, wherein said oligonucleotide analog compound is a morpholino oligomer composed of morpholino subunits linked by phosphorus-containing linkages between the morpholino nitrogen of one subunit and an exocyclic carbon at the morpholino 3-position of an adjacent subunit.

10. The improvement of claim 9, wherein said morpholino subunits are joined by uncharged phosphorodiamidate linkages, in accordance with the structure: 2where Y.sub.1=O, Z=O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, or alkyl amino.

11. A therapeutic oligomer-peptide conjugate, comprising (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which the compound is intended to bind, and (b) conjugated to said compound, an arginine-rich peptide effective to enhance the uptake of the compound into target cells, where said string of bases in the compound includes at least one inosine base, positioned in said string so as to limit the number of contiguous guanine bases in said string to three or fewer.

12. The conjugate of claim 11, wherein the position of one or more inosine bases in said compound is such as to limit the number of contiguous guanine bases in said string to two or fewer.

13. The conjugate of claim 12, wherein said compound includes at least two inosine bases in said string of bases.

14. The conjugate of claim 11, wherein said arginine-rich peptide comprises 8 to 16 subunits selected from X subunits, Y subunits, and optional Z subunits, including at least six X subunits, at least two Y subunits, and at most three Z subunits, where >50% of said subunits are X subunits, and where (a) each X subunit independently represents arginine or an arginine analog, said analog being a cationic .alpha.-amino acid comprising a side chain of the structure R.sup.1N.dbd.C(NH.sub.2)R.sup.2, where R.sup.1 is H or R; R.sup.2 is R, NH.sub.2, NHR, or NR.sub.2, where R is lower alkyl or lower alkenyl and may further include oxygen or nitrogen; R.sup.1 and R.sup.2 may together form a ring; and the side chain is linked to said amino acid via R.sup.1 or R.sup.2; (b) each Y subunit independently represents a neutral amino acid --C(O)--(CHR).sub.n--NH--, where (i) n is 2 to 7 and each R is independently H or methyl, or (ii) n is 1 and R is a neutral side chain selected from substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, and aralkyl, wherein said neutral side chain, when selected from substituted alkyl, alkenyl, and alkynyl, includes at most one heteroatom for every four carbon atoms; and (c) each Z subunit independently represents an amino acid selected from alanine, asparagine, cysteine, glutamine, glycine, histidine, lysine, methionine, serine, and threonine.

15. The conjugate of claim 14, wherein said oligonucleotide analog compound is a morpholino oligomer composed of morpholino subunits linked by phosphorus-containing linkages between the morpholino nitrogen of one subunit and an exocyclic carbon at the morpholino 3-position of an adjacent subunit.

16. The conjugate of claim 15, wherein said morpholino subunits are joined by uncharged phosphorodiamidate linkages, in accordance with the structure: 3where Y.sub.1=O, Z=O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, or alkyl amino.

17. The conjugate of claim 11, which has a greater water solubility during a purification step involving conjugate binding to and release from an cationic ion exchange resin than the same conjugate but for said one or more inosine bases.

18. The conjugate of claim 11, for use in blocking processing of a preprocessed mRNA at a selected donor or acceptor splice site in the target nucleic acid region of the preprocessed mRNA, which is more active in blocking such mRNA splice-site processing than the same conjugate but for said one or more inosine bases.

19. The conjugate of claim 11, for use in blocking viral replication in cells infected with a virus whose target nucleic acid region includes a cis-acting element essential for viral replication, which is more active in blocking such viral replication than the same conjugate but for said one or more inosine bases.

20. The conjugate of claim 11, for use in blocking translation of a protein encoded by an mRNA whose target nucleic acid region includes a start codon, which is more active in blocking such translation than the same conjugate but for said one or more inosine bases.

21. The conjugate of claim 20, wherein said compound (i) is targeted against a region including the AUG start site of human c-myc mRNA and (ii) includes a targeting sequence selected from the group consisting of SEQ ID NOS: 2-10.

22. The conjugate of claim 21, wherein said peptide includes a sequence selected from group consisting of SEQ ID NOS: 16, 17 and 18.

23. The conjugate of claim 11, wherein said peptide includes a sequence selected from group consisting of SEQ ID NOS: 16, 17 and 18.

24. A method of treating a subject having a pathological condition responsive to inhibition of c-myc expression in subject target cells, comprising administering to the subject, a therapeutically effective amount of an oligomer-peptide conjugate composed of (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target mRNA region that includes the mRNA start codon, and (b) conjugated to said compound, an arginine-rich peptide effective to enhance the uptake of the compound into such target cells, where (i) the base sequence of the compound includes, in said string of bases at least one inosine base, positioned in said string so as to limit the number of contiguous guanine bases in said string to three or fewer, and (ii) the conjugate is more active in blocking such translation than the same conjugate but for said one or more inosine bases.

25. The method of claim 24, wherein said arginine-rich peptide comprises 8 to 16 subunits selected from X subunits, Y subunits, and optional Z subunits, including at least six X subunits, at least two Y subunits, and at most three Z subunits, where >50% of said subunits are X subunits, and where (a) each X subunit independently represents arginine or an arginine analog, said analog being a cationic .alpha.-amino acid comprising a side chain of the structure R.sup.1N.dbd.C(NH.sub.2)R.sup.2, where R.sup.1 is H or R; R.sup.2 is R, NH.sub.2, NHR, or NR.sub.2, where R is lower alkyl or lower alkenyl and may further include oxygen or nitrogen; R.sup.1 and R.sup.2 may together form a ring; and the side chain is linked to said amino acid via R.sup.1 or R.sup.2; (b) each Y subunit independently represents a neutral amino acid --C(O)--(CHR).sub.n--NH--, where (i) n is 2 to 7 and each R is independently H or methyl, or (ii) n is 1 and R is a neutral side chain selected from substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, and aralkyl, wherein said neutral side chain, when selected from substituted alkyl, alkenyl, and alkynyl, includes at most one heteroatom for every four carbon atoms; and (c) each Z subunit independently represents an amino acid selected from alanine, asparagine, cysteine, glutamine, glycine, histidine, lysine, methionine, serine, and threonine.

26. The method of claim 25, wherein said oligonucleotide analog compound is a morpholino oligomer composed of morpholino subunits linked by phosphorus-containing linkages between the morpholino nitrogen of one subunit and an exocyclic carbon at the morpholino 3-position of an adjacent subunit.

27. The method of claim 26, wherein said morpholino subunits are joined by uncharged phosphorodiamidate linkages, in accordance with the structure: 4where Y.sub.1=O, Z=O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is alkyl, alkoxy, thioalkoxy, or alkyl amino.

28. The method of claim 27, wherein said compound includes a targeting sequence selected from the group consisting of SEQ ID NOS: 2-10.

29. The method of claim 27, wherein said peptide includes a sequence selected from group consisting of SEQ ID NOS: 16, 17 and 18.

30. The method of claim 29, wherein said compound includes a targeting sequence selected from the group consisting of SEQ ID NOS: 2-10.

31. The method of claim 24, for use in treating bladder cancer, wherein said conjugate is administered by transurethral delivery, and the method further includes administered a cis-platin anti-cancer compound to the patient.

32. The method of claim 24, for use in reducing the risk of coronary-artery restenosis at the site of vascular injury following an angioplasty procedure, wherein said conjugate is administered by intravascular delivery.

33. The method of claim 32, wherein said angioplasty procedure includes placement of a stent at the site of vascular injury, and said conjugate is administered by release from the stent.

34. The method of claim 24, for use in protecting an saphenous vein placed during a coronary bypass operation, and said conjugate is administered by exposing the vein to the conjugate prior to its surgical placement.

35. The method of claim 24, for treating polycistic kidney disease, wherein said conjugate is administered to the subject by oral or parenteral administration.

Brief Patent Description - Full Patent Description - Patent Claims

Click on the above for other options relating to this Peptide conjugated, inosine-substituted antisense oligomer compound and method patent application.
###

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.
Start now! - Receive info on patent apps like Peptide conjugated, inosine-substituted antisense oligomer compound and method or other areas of interest.
###

Previous Patent Application:
Oligonucleotides comprising a c5-modified pyrimidine
Next Patent Application:
Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
Industry Class:
Drug, bio-affecting and body treating compositions

###

Design/code © 2009 FreshContext LLC/Freshpatents.com. Website Terms and Conditions - Also read: About this Page
Patent data source: patents published by the United States Patent and Trademark Office (USPTO)
Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and often contain additional data/images (Freshpatents is currently text-only). FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents.

FreshPatents.com Support
Thank you for viewing the Peptide conjugated, inosine-substituted antisense oligomer compound and method patent info.
IP-related news and info

Results in 0.35335 seconds

Other interesting Feshpatents.com categories:
Software: Finance , AI , Databases , Development , Document , Navigation , Error 174

* Protect your Inventions
* US Patent Office filing

Provisional Patent
Utility Patent

PATENT INFO